Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether fish oils - a known source of omega-3 given intravenously (via a 'drip') will help cure secondary deposits in the liver from bowel cancer.


Clinical Trial Description

Fish oils have many proven benefits for a wide range of clinical arenas such as ischaemic heart disease, rheumatoid arthritis and inflammatory bowel disease.

Recent research has described the beneficial effects of intravenous fish oils for surgical patients, such as reduced hospital stay, reduced re-operation rate and reduced requirements for intravenous antibiotics. These are in part due to the anti-inflammatory effects of fish oils.

There is evidence that fish oils are also effective against cancer, large population studies indicate that diets rich in omega-3 are associated with a lower incidence of cancer, and in vitro and animal studies demonstrate anti-tumour effects of fish oils

1. Fish oils inhibit the growth of different human cancer cell lines

2. They act specifically on tumour cells only and do not impair the function of normal cells

3. EPA and DHA inhibit the growth of human cancer cell lines and enhance apoptosis.

4. Fish oil induces apoptosis in human colorectal cancer cell lines in-vitro after 48hrs incubation

5. Fish oil has been shown to inhibit the proliferation activities, inhibit the invasive activities and increase the apoptosis of human pancreatic carcinoma cell lines in-vitro after only 48hrs of exposure

6. Fish oil has been shown to enhance colorectal adenocarcinoma cell lines sensitivity to radiotherapy

7. Fish oil has also been shown to reduce the incidence of liver metastases in experimentally induced ductal pancreatic cancer in rats after 30 weeks of oral treatment with an omega-3 supplemented diet.

8. Lung cancer xenografts in animals fed with fish oil showed significantly increased tumour regression in response to doxorubicin compared to those fed with omega-3.

This study aims to assess the effect of omega-3 FA upon hepatic colorectal metastases in a pilot study. 20 patients will be selected for this pilot study with potentially resectable hepatic colorectal adenocarcinoma metastases. 10 patients will receive total parenteral nutrition (TPN) without fish oils (controls), 10 will receive fish oil containing lipid emulsion in their TPN.

Changes in tumour angiogenesis (increased angiogenesis is associated with a poorer prognosis in hepatic colorectal metastases) will be investigated using digital contrast enhanced MRI scanning, and markers of angiogenesis will be investigated in blood and resected tumour samples from the patients.

It is a randomised controlled double blind trial. ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00942292
Study type Interventional
Source University Hospitals, Leicester
Contact
Status Completed
Phase Phase 2
Start date May 2007
Completion date October 2010

See also
  Status Clinical Trial Phase
Completed NCT01255007 - Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases N/A
Completed NCT00779272 - Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases N/A
Active, not recruiting NCT00797251 - Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression N/A
Recruiting NCT06045286 - High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM Phase 1
Recruiting NCT04870879 - Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors N/A
Completed NCT01799044 - Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases Phase 1
Terminated NCT00508872 - Folfox-B Study for Patients With Colorectal Liver Metastases Phase 2
Recruiting NCT05877001 - The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases Phase 2
Completed NCT02082782 - Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases Phase 2
Recruiting NCT01191632 - Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases Phase 1/Phase 2
Completed NCT00119899 - Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases Phase 3
Completed NCT00184834 - Quality of Life and Liver Metastases N/A
Completed NCT00557557 - Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases Phase 1
Recruiting NCT05468593 - Patient Outcomes After Hepatic Artery Infusion Pump Placement
Completed NCT02615665 - Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases N/A
Terminated NCT01318447 - CyberKnife® for Hepatic Metastases From Colorectal Cancer Phase 2
Completed NCT00885950 - Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants N/A
Completed NCT02331641 - Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases. N/A
Completed NCT00600522 - Alternative Surgical Policy for Central Liver Tumors N/A
Recruiting NCT05265169 - Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM) N/A